AstraZeneca (NASDAQ: AZN) — Company Overview, News & Financial Data
AstraZeneca is a global biopharmaceutical company focused on developing prescription medicines across multiple therapeutic areas.
AZN AstraZeneca
Company profile
AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company concentrates its scientific research and commercial operations on prescription pharmaceuticals across major therapeutic areas, including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, Vaccines & Immune Therapies, and Rare Diseases. Headquartered in the United Kingdom, it operates major strategic research and development centers alongside production facilities and commercial networks serving patients in over one hundred countries worldwide.
Snapshot
Public USOwnership
1913Year founded
~71,000Employees
Cambridge, United KingdomHead office
Loading Map...
Global footprint
Operations
Products and/or services of AstraZeneca
- Oncology Therapies: Discovery and commercial distribution of targeted cancer medicines, immuno-oncology agents, and antibody-drug conjugates for lung, breast, ovarian, prostate, and hematological malignancies across major healthcare markets in North America, Europe, and Asia-Pacific.
- Cardiovascular, Renal and Metabolism Medicines: Provision of small molecule and biologic therapeutics aimed at managing chronic kidney disease, heart failure, type 2 diabetes, and metabolic conditions, distributed globally through hospital and retail pharmacy channels.
- Respiratory and Immunology Treatments: Development and supply of inhaled formulations, monoclonal antibodies, and biologic therapies designed for severe asthma, chronic obstructive pulmonary disease, chronic rhinosinusitis, and systemic autoimmune conditions worldwide.
- Rare Disease Therapeutics: Development and commercialization of specialized biologics and complement system inhibitors targeting rare genetic, metabolic, and hematological disorders, operating primarily through specialized rare disease business units and healthcare facilities globally.
- Vaccines and Immune Therapies: Production and distribution of viral vector vaccines, long-acting monoclonal antibody treatments, and biological agents for respiratory syncytial virus, coronavirus, and other infectious diseases across international health systems.
- Global R&D and Manufacturing Operations: Operation of major strategic research centers in Cambridge, Gothenburg, and Gaithersburg, paired with global pharmaceutical manufacturing networks that produce active pharmaceutical ingredients and finished dosage formulations worldwide.
AstraZeneca executive team
- Pascal Claude Roland SoriotCEO & Executive Director
- Aradhana SarinCFO & Executive Director
- Pam P. ChengEVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board
- Joris SilonHead of Investor Relations
- Jeffrey PottCHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board
- Ruud DobberExecutive Vice-President of BioPharmaceuticals Business Unit
- Susan Mary GalbraithExecutive Vice President of Oncology R&D
- Iskra ReicExecutive Vice President of International
- David FredricksonExecutive Vice-President of Oncology Haematology Business Unit
- Ruth MarchSenior VP of Precision Medicine - R&D Oncology
Latest news about AstraZeneca
AstraZeneca revenue advances 7% in Q3 to $16.21 billion
United StatesEnhertu wins EU approval with 53% lower recurrence risk
United StatesInnate Pharma delays PACIFIC-9 trial data to 2027
United StatesOracle and AstraZeneca announce AI healthcare collaboration
United StatesSummit Therapeutics completes $2 billion AstraZeneca equity investment
United StatesSummit partners with AstraZeneca and Daiichi Sankyo on ivonescimab
United States
Dividend history
Dividends per share paid by AstraZeneca , by financial year.
| Financial year | Interim | Final | Special | Total |
|---|---|---|---|---|
| FY2026(to date) | — | — | — | $5.4077 |
| FY2025 | — | — | — | $6.2700 |
| FY2024 | — | — | — | $3.9541 |
| FY2023 | — | — | — | $2.8719 |
| FY2022 | — | — | — | $2.8631 |
Key financials
Reported results for AstraZeneca , in USD.
- Market cap
- 289.4B
- Revenue (TTM)
- 62.4B
- P/E ratio
- 26.4
- EPS (diluted, TTM)
- 7.1
- Dividend yield
- 1.7%
- Profit margin
- 17.7%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 58.7B | 13.7B | 10.3B | |
| 54.1B | 10B | 7B | |
| 45.8B | 8.2B | 6B | |
| 44.4B | 3.8B | 3.3B |